Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE) The objective of the investigation is to document the safety and effectiveness of the ABV-1701 OE when compared to the SF6 Gas OE.

Inclusion Criteria:

1. Male or female adults aged 18 years or older on the day of screening;

2. Uncomplicated retinal detachment defined as one of the following:

   1. The first instance of a small macular hole (<400 microns)
   2. The first instance of a single small (<400 microns) primary tear extending less than 2 clock hours. There is no limit on the number or the position of the break(s). The tear can be PVR grade A (Vitreous haze and pigment clumps) or B (Surface retinal wrinkling, rolled edges of the retinal, retinal stiffness, and vessel tortuosity), but not more than grade B

3. Scheduled vitrectomy with vitreous substitute;

4. Must be able and willing to provide written informed consent, attend all scheduled visits and comply with all study procedures;

Exclusion Criteria:

1. Any active intraocular or periocular infection or inflammation;

2. Vitreous haemorrhage

3. Complicated Retinal detachments due to the following:

   1. Detachment due to Trauma
   2. Detachment due to Uveitis
   3. Chronic detachments defined as 2 or more surgeries
   4. PVR grade CA

4. Only one functional eye;

5. Ocular disorders in the study eye that could confound the interpretation of the study results. i.e. macular edema not requiring vitrectomy surgery, choroidal neovascularization;

6. High refractive error demonstrating >6 diopters of myopia;

7. An ophthalmic condition that reduces the clarity of the ocular media that may interfere with ophthalmic examination or imaging. i.e. Cataract, corneal opacity;

8. Uncontrolled glaucoma defined as intraocular pressure >30 mmHg on maximal therapy;

9. Aphakia or the absence of the posterior capsule;

10. Known hypersensitivity to hyaluronic acid or acid dihydrazide (ADH);

11. Uncontrolled blood pressure defined as systolic value >160 mmHg or diastolic value > 100 mmHg at screening;

12. Uncontrolled diabetes defined as glycated hemoglobin (HbA1c) >12%;

13. Pregnant or breastfeeding at the time of screening;

14. Women of childbearing potential, defined as women physiologically capable of becoming pregnant unless using effective methods of contraception during the study period. The effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) is not acceptable.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).
    • Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).

15. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device.

16. Any clinical evidence that the investigator feels would place the participant at increased risk with the investigational product.